Additional information
| Editors | |
|---|---|
| Publication Year | 2024 |
| ISBN | 90-6299-328-1, 978-90-6299-328-4 |
| Pages | 258 |
| Publisher | |
| Biblio | Hardbound. US letter format. |
Glaucoma Research and Clinical Advances- Volume 4
€90,00 excl. VAT
Description
New Concepts In Glaucoma Series
This series has been conceived as a recurring project. It is neither book nor journal. Books are infrequently edited and rarely up-to-date for more than a year or two; journals are really devoted to the standard experimental format and no longer permit authors to wander into speculation or lengthy discussions of what might come next. There is room for a plurality of publishing approaches. All of these formats have their place and all have different purposes in moving a field forward.
This series is designed to allow us to consolidate new information and hold forth on speculation in glaucoma. It does so in both the basic sciences and clinical sciences. It is our hope that this consolidation of hypotheses and theories, along with identifying new information and new speculation will propel us toward a more rapid cure for glaucoma.
Preface vii
Basic science
1. MicroRNA regulation of fibrosis in the trabecular meshwork
Breedge Callaghan, Chelsey Doyle, Carl Sheridan, Colin E. Willoughby
2. Intraocular pressure control through linked trabecular meshwork and collector channel motion
Murray Johnstone
3. Real-time effects of vasoregulators on distal outflow vessels in human anterior segments
Fiona S. McDonnell, Megan S. Kuhn, Kristin M. Perkumas, Heather M. Schmitt, Bre’Ida J. Riddick, Joseph van Batenburg-Sherwood, Alex S. Huang, Darryl R. Overby, W. Daniel Stamer
4. Prostanoid receptor gene expression in human and murine anterior ocular segment
Emily Adis, Betsy Benitez, Anna Mueller, Sanjoy Bhattacharya
5. Nychthemeral rhythms of aqueous humor dynamics
Carol B. Toris
Clinical and drugs
6. Omidenepag isopropyl: a novel first-in-class non-prostaglandin selective EP2 receptor agonist drug that efficaciously lowers and controls IOP in multiple species with minimal side effects
Najam A. Sharif, Tim Collinson, Fenghe Lu, Noriko Odani-Kawabata
7. Stanniocalcin-1, a novel ocular hypotensive agent with capacity for sustained intraocular pressure reduction
Gavin W. Roddy, Michael P. Fautsch
8. Blood pressure and glaucoma: can physiology-enhanced artificial intelligence solve the enigma?
Rebecca Kellner, Alon Harris, Lauren Ciulla, Rajat Rai, Brent Siesky, Fotis Topouzis, Alice Verticchio Vercellin, Gal Antman, James Keller, Daphne Zou, Christopher K. Wikle, Giovanna Guidoboni
Lasers and surgery
9. Laser-induced hyperthermia for the management of glaucoma
Giorgio Dorin, John R. Samples
10. Traditional continuous wave cyclophotocoagulation versus micropulse cyclophotocoagulation: what’s the difference?
Ellen Yang, Michael Zein, Thomas Patrianakos, Michael Giovingo
11. New and upcoming MIGS
Josiah K. To, Thomas Patrianakos, Michael C. Giovingo
12. Glaucoma in myopic eyes
Abdelrahman M. Elhusseiny, Sarwat Salim
Trabecular meshwork
Trabecular Meshwork Study Club Abstracts 2023
Volume 4 of our series of publications continues to address basic and clinical glaucoma with the same combination of science and speculation that appeared in the prior 3 volumes. The individual chapters address the basic science that underlies contemporary clinical concerns. Thus, the subject area of each chapter is targeted to advance glaucoma care, including some pharmacologic agents that are not currently available in the marketplace. Regardless, these new glaucoma drugs have been shown to be efficacious, targeting new mechanisms that control intraocular pressure.
We are fortunate to be able to continue this series with support from Simon Bakker at Kugler Publications and Dr. W. Daniel Stamer, who will serve as lead editor for Volume 5. Its planned focus is the biomechanics of the trabecular meshwork (TM), inspired by the tremendous progress over the past 20 years in TM biomechanics and the success of 2 corneal biomechanics books led by Cynthia Roberts, also available from Kugler Publications.
These TM-focused chapters have a rich foundation in the annual meeting of the Trabecular Meshwork Study Club, which is now 24 years old. We meet as a satellite preliminary meeting of the American Society for Cell Biology (ASCB), under the belief that ASCB has many novel insights to propel glaucoma science generally and outflow science specifically. Based on the authors’ desire to be included in this volume, a few abstracts from the Trabecular Meshwork Study Club’s last meeting appear at the end of this book. In addition to these volumes, the Trabecular Meshwork Study Club has produced a series of white papers that are intended to serve as “accepted practices” in TM biology. Furthermore, the restrictions brought on by COVID catalyzed the creation of an online TM seminar series sponsored by the Bright Focus Foundation, which continues and is widely attended to this day. The virtual series is open to all and information on dates and topics can be obtained by writing to glaucoma@gmail.com.
Questions? Comments? Do you want to make a contribution to support research that aims to develop better glaucoma treatments? You can write to the Western Glaucoma Foundation at glaucoma@gmail.com, or find us
and Simon Bakker at the American Glaucoma Society, the European Glaucoma Society, the Asia-Pacific Glaucoma Society, and the Association for Research in Vision and Ophthalmology. We thank you for your interest in outflow biology.
John R. Samples, MA, MD
Professor, Washington State University College of Medicine, Spokane, WA, USA
glaucoma@gmail.com
W. Daniel Stamer, PhD
Professor of Ophthalmology, Duke University School of Medicine, Durham, NC, USA
